|Home | About | Journals | Submit | Contact Us | Français|
Several recent oral oncology drug labels were labeled to be administered in fasted states despite the fact that food increases their bioavailability. Since this was inconsistent with principles of oral drug delivery, we hypothesized that there were inconsistencies across therapeutic areas.
Oral agents approved by US FDA from January 2000 to May 2009 were included in our study. Comparison of the food labeling patterns between oncology and non-oncology drugs was made using Fisher's exact test.
Of 99 drugs evaluated, 34 showed significant food effects on bioavailability. When food markedly enhanced bioavailability, 8 out of 9 non-oncology drugs were labeled “fed” to take advantage of the food-drug interaction while all oncology drugs (n=3) were labeled to be administered in “fasted” states (Fisher's exact; p= 0.01).
Drug labeling pattern with respect to food-drug interactions observed with oncology drugs is in contradiction to fundamental pharmacological principles, as exemplified in the labeling of non-oncology drugs.
Many new antineoplastic agents are intended for daily administration requiring the availability of oral formulations. Oral therapies can improve a patient's quality of life by offering convenience and a sense of control, as well as avoiding the cost of administering parenteral agents.(1, 2). However, oral cancer drugs can present special challenges. With increased patient responsibility, non-adherence to potent agents is a major concern to oncologists.(3) In addition, oral agents generally have more complex pharmacokinetic challenges compared to the drugs administered intravenously.
Administration of oral drugs with meals can influence drug absorption and systemic exposure. The food effect on oral bioavailability is the result of a complex interplay of drug, formulation, intestinal physiology, and meals. As food can either increase or decrease bioavailability, the interaction should be studied early in drug development to provide rational dosing recommendations for the pivotal clinical trials.(4)
Questions were raised in the recent past regarding the labeling of lapatinib, a dual tyrosine kinase inhibitor used to treat advanced breast cancer.(5) Lapatinib is labeled to be taken fasting, despite the fact that food markedly improved bioavailability of the drug, exemplifying a missed opportunity to take advantage of pharmacologically favorable food-drug interactions.(6) We hypothesized that there might be a systematic difference between oncology and non-oncology products in terms of food labeling. The present work examines food labeling pattern of oncology and non-oncology drugs to highlight the inconsistency across the therapeutic areas and to suggest potential implications.
The present study is based on examination of all new molecular entities (NME) that were approved for oral administration by the United States Food and Drug Administration (FDA) between January 2000 and May 2009. The primary source of data was the FDA website (http://www.accessdata.fda.gov/scripts/cder/drugsatfda). This included both clinical pharmacology/biopharmaceutics reviews and labels. A search of published literature was conducted in PubMed (http://www.ncbi.nlm.nih.gov/pubmed) to gather missing information from the FDA website.(7-19) Main search terms used were food effect, bioavailability, pharmacokinetics, and the agents' names.
Data captured for the purpose of the present analysis included drug approval date, drug name, therapeutic area, magnitude of food effect, interindividual variability of area under the curve (AUC) of fed and fasted states, dosing recommendation with regards to meals (fed, fasted, or either), and black box safety warning in drug labels.
We included all NMEs with food effect bioavailability study results available on the FDA website or via publication, and divided them into two categories (oncology versus non-oncology) based on their indications and divisions of US FDA involved in the approval processes. We used AUC as the reflection of the extent of drug exposure, and used the ratio of fed to fasted AUC to measure the food effect. In keeping with Guidance from FDA, food effect was determined to be significant if the AUC ratio (fed: fasted) was greater than 1.25 or less than 0.8.(20) We then sub-classified NMEs with the ratio greater than 1.5 and less than 0.5, a magnitude of food effects that will likely have clinical implications. Comparison of food effects was made between oncology and non-oncology drugs that met these criteria.
The dosing recommendations regarding meal intakes (fasted, fed, or either) available in dosage and administration section of package inserts were surveyed in order to study how food effect study results are applied. Comparison of the drug label patterns between oncology and non-oncology drugs with marked food effects were made by using Fisher's exact test.
In order to assess the impact of food intake on inter-individual variability (IIV) of AUC, we compared coefficient of variation (CV) of AUC between fasted and fed states of 23 drugs with significant food effects and available PK data. Black box safety warnings were available from package inserts and the frequency of black box warnings were compared between oncology and non-oncology drugs. We also surveyed package inserts of NMEs with black box warnings to identify warnings related to food intake and associated risks.
We identified 104 oral NMEs that were approved by FDA between January 2000 and May 2009. This included 11 oncology drugs and 93 non-oncology drugs. Most of these NMEs (n=99) had food effect study results reported in the clinical pharmacology section of the package inserts.
Of 99 NMEs with available food effect study results, about one-third (n=34) showed significant food effects on their bioavailability. Marked food effects were observed in nearly 20% of drugs (14 increasing and 4 decreasing AUC). Of the 18 NMEs with marked food effects, 3 were oncology agents and 15 were non-oncology agents.
The vast majority (94%, n=93) of NMEs had specific recommendations with respect to food co-administration: 60% (n=56) without regard to meals, 24% (n=22) to be administered with food, and 16% (n=15) to be administered in fasted state. Only 6 NMEs had no specific recommendations regarding food intake.
Analysis of 14 NMEs with marked increase in AUC with food revealed that there are different food labeling patterns between oncology and non-oncology drugs. For the non-oncology drugs, the marked increase in bioavailability with food generally (with one exception,) led to recommendations to administer drugs in a fed state to take advantage of the favorable food effects. The opposite labeling pattern was observed for oncology drugs, as all three drugs with a marked increase in bioavailability with food were recommended to be administered in fasting states.
Food significantly decreased (by ≥ 20%) the bioavailability of 11 NMEs, and the majority were labeled to be administered in fasted state (7 fasted, 1 fed, and 3 either). Sorafenib was the only oncology NME in this group, which is labeled to be taken fasting. Four NMEs showed a marked decrease of bioavailability (by ≥ 50%) with food, and all of them were labeled to be administered in a fasted state to maximize their bioavailability. FIGURE1
Of 34 NMEs with significant food effects, 23 had CV data available through the FDA website (Package insert or Clinical Pharmacology and Biopharmaceutics Review) or via publications. TABLE 1 In general, we observed an inverse relationship between food effects on bioavailability and IIV. In most cases, increase of bioavailability with food resulted in decrease of IIV of AUC. Figure 2 Of 16 drugs with significant increase of bioavailability with meals (and with available CV data), only one drug (posaconazole) showed an increase of bioavailability associated with a slight increase of IIV; the CV increase with food was merely 5%. The CVs of three oncology drugs with marked positive food effect were decreased by food intake, which indicate that co-administration of drugs with food did not add to the risk of unpredictable exposure, but in fact improved the exposure variability probably as a result of enhanced bioavailability. On the other hand, when food had a negative effect on a drug's bioavailability, administering the drug with food resulted in greater IIV compared to administering it without food. FIGURE 2
We surveyed NMEs with a blackbox safety warning in order to determine whether marked food-drug interactions are incorporated in such warning. The frequencies of blackbox warnings were similar between oncology and non-oncology drugs (36% VS 32%). Of three drugs with marked food-drug interactions, only one NME (nilotinib) had its food effect on drug exposure clearly described in the blackbox safety warning. Lapatinib, which showed the greatest food effect on its AUC, did not have a blackbox warning regarding its food-drug interaction, even though QT prolongation is an acknowledged risk. TABLE 2
Dosing strategies to enhance bioavailability offer several advantages to delivery of oral drugs. They include reduced gastrointestinal toxicity (from unabsorbed drug) and decreased intra-individual and/or inter-individual variability in drug exposure.(4, 21) FIGURE 3 Increased drug absorption also reduces wasted drug product and improves pharmacoeconomic efficiency.
Unwarranted food restrictions may compromise practicality of drug administration for patients and result in decreased adherence. The complexity of the drug regimen is a major reason for non-adherence, and interventions such as reminder systems have been shown to improve adherence. (3, 22-26) Daily routines such as breakfast, can serve as great reminders to take medications consistently. Hence, a dosing schedule tied to routine meals will be easier for patients (particularly elderly cancer patients taking multiple oral medications) and can be a great way to improve adherence, which is recognized as a serious challenge in cancer treatments with oral agents.
The food labeling pattern of recently approved oral oncology drug products is inconsistent with fundamental principles of oral drug delivery. The labels of three agents (erlotinib, nilotinib, and lapatinib) minimize bioavailability through food restrictions, which is in contrast to labeling principles used for all other classes of oral agents. In the absence of a scientific basis for food restrictions, one can hypothesize that the atypical food labeling pattern of some oral oncology drug products may be a consequence of external pressures (corporate and regulatory pressures) in an era of immense competition in oncology. Phase II (and occasionally registration) studies are often initiated prior to completion of an appropriate food-effect study.(14, 27) Since the default position appears to be fasting, this has occasionally resulted in completion of all clinical studies with a fasting dosing regimen, in the absence of adequate supportive pharmacokinetic data. (14, 27, 28) Furthermore, there is little interest by industry in conducting such studies later if the result would be a lower labeled dose, since this would result in reduced revenues, unless accompanied by an increase in pricing. Thus, regulators should require such studies after approval, if the prior studies have not adequately addressed this issue.
A food effect study conducted in a timely fashion can facilitate pharmacologically rational drug dosing strategies. The optimal time for studying food-drug interactions would be at the end of the first phase I clinical trial: once the dose-toxicity relationship has been identified. At the very minimum, the appropriate prandial state(s) should be determined before undertaking pivotal trials, given the importance of such trials in drug labeling.
It should also be noted that food restriction in the first phase I clinical trial, before the characterization of food effect, is not ideal from standpoints of pharmacology and patient safety. Since a marked decrease of AUC with food is uncommon, it is probably most appropriate – in the absence of data – to begin studies of NMEs in a fed state. On the other hand, nearly 15% of recently approved NMEs showed a marked increase in bioavailability with food. Starting the first phase I trials in fed conditions will reduce the risks of severe adverse events due to inadvertent food-drug interactions.
We recognize the limitation of this retrospective analysis, particularly in regard to identifying the rationale for apparently irrational decisions given the complex nature of oncology drug development processes and decision-making. There are potential limitations in comparing drug labels of oncology and non-oncology drugs due to different potencies, indications, and targeted patients. Inability to study other factors relevant for food labeling, such as comparison of IIV of drug exposures between prandial states with differing food contents, due to lack of such data, is another limitation of this report. Despite these limitations, our analysis clearly illustrates a distinct food labeling pattern with oncology products that is inconsistent with fundamental principles routinely practiced in other disciplines. While there is understandable urgency that may be unique to oncology, it is important that regulatory agencies insist on uniform application of principles of clinical pharmacology, regardless of the impact on the sponsor's timelines.
Dr. Soonmo Peter Kang was supported by Clinical Therapeutics T32 GM007019 from NIH
Translational Relevance: Knowledge of food-drug interactions is critical in optimizing delivery of oral anticancer agents. We found a systematic difference between oncology and non-oncology drugs in how food-drug interactions are applied in their labels. When food enhanced bioavailability, non-oncology drugs were labeled “fed” to take advantage of the food-drug interaction while oncology drugs were labeled to be administered in “fasted” states. These oncology drug labeling decisions are in contradiction to fundamental pharmacological principle as exemplified in non-oncology drugs; therefore, they may lead to suboptimal dosing strategies and outcomes. While there is understandable urgency that may be unique to oncology, it is important that regulatory agencies insist on uniform application of principles of clinical pharmacology in oncology drug development.
Author Contributions:Concept: Ratain.
Acquisition of data: Kang, Ratain.
Analysis and interpretation of data: Kang, Ratain.
Drafting of the manuscript: Kang, Ratain.
Statistical analysis: Kang, Ratain.